Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis. - Wikidata - wikimedia - TriplyDB

Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis.

Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis.

http://www.wikidata.org/entity/Q42742359

about

Epigenetic contributions in the development of rheumatoid arthritis Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009 Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro.Helper T cell plasticity: impact of extrinsic and intrinsic signals on transcriptomes and epigenomes.Strategies for controlled delivery of biologics for cartilage repair.Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer Antitumor mechanisms of amino Acid hydroxyurea derivatives in the metastatic colon cancer model.Histone deacetylase inhibition activates Nrf2 and protects against osteoarthritis Histone Deacetylases in Bone Development and Skeletal Disorders.Histone deacetylases inhibitor Trichostatin A ameliorates DNFB-induced allergic contact dermatitis and reduces epidermal Langerhans cells in mice Histone deacetylase 3 suppression increases PH domain and leucine-rich repeat phosphatase (Phlpp)1 expression in chondrocytes to suppress Akt signaling and matrix secretion Epigenetic targets for reversing immune defects caused by alcohol exposure.HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis.HDACi: molecular mechanisms and therapeutic implications in the innate immune system.Histone deacetylase inhibitors as suppressors of bone destruction in inflammatory diseases.Epigenetics in rheumatoid arthritis: a primer for rheumatologists.Glucocorticoid sensitivity in health and disease.Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.Epigenetics and Bone Remodeling.Epigenetic drug discovery: breaking through the immune barrier.The acetyl code in rheumatoid arthritis and other rheumatic diseases.Class I histone deacetylase inhibition modulates metalloproteinase expression and blocks cytokine-induced cartilage degradation.Epigenetic alterations in rheumatoid arthritis fibroblast-like synoviocytes.Histone deacetylase inhibitor vorinostat (SAHA, MK0683) perturb miR-9-MCPIP1 axis to block IL-1β-induced IL-6 expression in human OA chondrocytes.Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay.Suppression of monosodium urate crystal-induced cytokine production by butyrate is mediated by the inhibition of class I histone deacetylases.Histone Deacetylase Inhibitor Vorinostat (SAHA) Suppresses IL-1β-Induced Matrix Metallopeptidase-13 Expression by Inhibiting IL-6 in Osteoarthritis Chondrocyte Histone deacetylase inhibitors restore IL-10 expression in lipopolysaccharide-induced cell inflammation and reduce IL-1β and IL-6 production in breast silicone implant in C57BL/6J wild-type murine model.Epigenetics of inflammatory arthritis.Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice.A novel histone deacetylase 6-selective inhibitor suppresses synovial inflammation and joint destruction in a collagen antibody-induced arthritis mouse model.Class I and II histone deacetylase expression in human chronic periodontitis gingival tissue.Immunopathogenesis of Rheumatoid Arthritis.The Emerging Spectrum of Early Life Exposure-Related Inflammation and Epigenetic Therapy

P2860

Q26849371-67FB949B-DB36-4EBE-AADD-4BDF3821D08C Q33654202-EAFEE5C6-09EC-43BC-8F56-5CC4549D812B Q33869272-52DF4290-036B-45AC-BEDD-7FC275E87E80 Q34356521-FA1AFD67-19D2-4C13-8861-7A6EE500A8BE Q34791411-4707A564-8478-4531-AE06-D573C0AE8571 Q35016934-63CAF5E6-244D-4E12-A264-35E4657D87B1 Q35058878-29CF756E-9B1B-47F7-A6E1-7A293FA2FC8D Q36095497-29B7C143-9640-4D5C-9FF8-51B484C81419 Q36146330-3069EB15-B622-4280-8CF9-ACEFC57591AB Q36351364-08968EC3-B401-4577-9DF0-2B882ABD9F32 Q36742145-FB1F4F3E-50AE-473C-BD49-8DD6E5647D43 Q37386440-007E1953-64BE-41BB-869D-E4476FA8B279 Q37838731-981AE368-3A34-4BBD-BDC9-AD3B1B9C7F89 Q37956176-33023EF5-6CBE-4657-9F4D-5AC9EF383A2E Q38008692-A0F5030E-BE03-4734-AD45-DD6FF4DB9241 Q38145001-31711D67-5202-4C23-A3DC-3071D4687423 Q38147870-FADC8AA4-854E-4D5C-ACC1-478BC4663512 Q38240733-C0FDEBE9-7F09-4EA8-A634-19AF40E618DB Q38624611-E2978ED0-596F-4A55-876F-9B9C13CCB502 Q38986705-FDAEAA76-9805-4C68-8172-69FD51B73873 Q39094945-949592B6-2357-45F8-BF8D-059015E9118D Q39168362-0A101771-B546-42A0-860E-482F0A6829EE Q39189613-4F61396D-B0E9-48B7-A38E-6299852FBE83 Q39609958-9C7E1AF5-AE81-41E2-8CB8-F5C96FBE5B8F Q41042385-B4BFB982-FB56-4E39-A907-AA71A01DC961 Q41544554-42038704-FCF7-473C-BF9E-8E556535B162 Q41630267-EE3A3525-B0E7-490D-843C-074BCB5BFFFB Q42815246-2E7F7D09-A32B-4ABD-A8BA-10312A3EFC58 Q45967099-23D9F089-E93A-4046-AFCF-E28F635D76D8 Q50067303-C7F03F0F-3270-4710-AEA1-DC5B36887883 Q53662447-EBBE0C05-3EFA-40B7-AFC0-931FAEDB31EC Q54161049-5D6F420C-6D79-461F-BEA3-B63180AD386A Q54430437-798CFA93-0FAB-4449-8B2F-7E4BA7FA20E4 Q59125138-A9607421-4AD2-4108-A9AE-B4D055DCC066

P2860

Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis.

http://www.wikidata.org/entity/Q42742359

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Inhibition of HDAC activity by ...... ion in experimental arthritis.

@en

Inhibition of HDAC activity by ...... ion in experimental arthritis.

@nl

type

label

Inhibition of HDAC activity by ...... ion in experimental arthritis.

@en

Inhibition of HDAC activity by ...... ion in experimental arthritis.

@nl

prefLabel

Inhibition of HDAC activity by ...... ion in experimental arthritis.

@en

Inhibition of HDAC activity by ...... ion in experimental arthritis.

@nl

P1433

Q42742359-7446C15C-5C14-4751-8848-7384C84D65B2

P1476

Q42742359-116924B7-AD66-414A-95E7-D9659C09765A

P2093

Q42742359-3F4C25BA-C240-4CE1-9288-AAC1F54B3599

Q42742359-585DACCE-7B5D-4DEF-8EB7-A39E0610F655

Q42742359-60E8E2AB-D4F6-4EDF-968C-2AE5487B680B

Q42742359-C12AEF48-8243-4EE7-9229-77307D142C80

P2860

Q42742359-00244EE8-BB2A-4D46-9565-7534476EB0E3

Q42742359-015E3A8C-164B-4FDD-B4BF-57DFC0E5EA39

Q42742359-01EFE11D-CEB9-44B7-8539-8C6DA235540B

Q42742359-04FD3731-6195-4BE4-A8B6-BF16A46D1B57

Q42742359-06826517-6F32-4B75-8E17-48FF10279148

Q42742359-0D65DE75-FFC0-4B50-9AD0-540F97F2C49B

Q42742359-15F4E85A-AA2F-4A36-AF25-1C4F48131DAA

Q42742359-23C9FD68-73C5-4AFC-A90A-E6958E68AD52

Q42742359-3CD5EF14-9E63-48A4-AA0C-110F4AAB03F2

Q42742359-3F79DB91-E93C-43DD-A75A-4BE2842113B5

P2888

Q42742359-99C897EF-92C5-428E-BCA6-8C6708D2D11D

P304

Q42742359-88D9647E-B1DB-46FE-91A7-9714E75929E7

P31

Q42742359-9A67B20D-B2BE-4F30-B818-8B45444C6E09

P356

Q42742359-E8821052-18CB-462C-BF61-58EB19D1998E

P407

Q42742359-51159856-84E9-499D-A3E4-C8A0F822C337

P433

Q42742359-A434ECBE-2667-4EBD-890E-F090378184C5

P478

Q42742359-C043FDDA-DCDE-46B8-BD85-71112B459173

P577

Q42742359-9689632D-F3B4-4541-9ED6-73058118ACCB

P5875

Q42742359-DE647F07-0DFA-433F-8D75-F44F0356C22E

P6179

Q42742359-432B9283-CD6C-4525-B7E2-02B0D371EBCC

P698

Q42742359-FCD223A7-8E02-4A18-9FDC-3535E2992221

P921

Q42742359-CA99751F-9EC5-42C2-8C93-6C797EC3CDCA

P932

Q42742359-52750A9A-30D6-4A45-B9E7-531AC5100C8D

P356

MOLMED.2011.00058

P1433

Molecular Medicine

P1476

Inhibition of HDAC activity by ...... ion in experimental arthritis.

@en

P2093

Flavio Leoni

http://www.w3.org/2001/XMLSchema#string

Leo A B Joosten

http://www.w3.org/2001/XMLSchema#string

Paolo Mascagni

http://www.w3.org/2001/XMLSchema#string

Sajeda Meghji

http://www.w3.org/2001/XMLSchema#string

P2860

Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.

Interleukin-1 is essential for systemic inflammatory bone loss.

Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury.

Correlation between MMP-13 and HDAC7 expression in human knee osteoarthritis.

The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.

Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis

Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.

The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo

Histone deacetylases and cancer: causes and therapies.

P2888

molmed.2011.00058

P304

391-396

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2119/MOLMED.2011.00058

http://www.w3.org/2001/XMLSchema#string

P407

P433

5-6

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49841901

http://www.w3.org/2001/XMLSchema#string

P6179

1068965376

http://www.w3.org/2001/XMLSchema#string

P698

21327299

http://www.w3.org/2001/XMLSchema#string

P921

P932

3105133

http://www.w3.org/2001/XMLSchema#string